In view of the corona-crisis, a review of the Medicover case makes us conclude that the current stock weakness is overdone and represents an opportunity to build exposure at an attractive price. While fundamental risks admittedly have risen of late, however, we leave our estimates unchanged at this point still predicting solid results for the year as a whole.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se